Joe Wiley

20 results

Amryt Pharma focuses on developing treatments to help patients with rare and orphan diseases. Photograph: iStock

Amryt Pharma, a Dublin-based biopharmaceutical company, said integration of Aegerion Pharmaceuticals, a company it acquired in September, is “progress(...)

‘Amryt is now very well-positioned to execute on our strategy of becoming a global leader in the rare and orphan disease space.’ Photograph: iStock

Amryt Pharma, the Dublin-based biopharmaceutical company, grew sales almost 20 per cent in the first nine months of its financial year, helped by sign(...)

Photograph: iStock

Amryt, an Irish pharmaceutical company focused on rare diseases, has agreed to acquire Aegerion Pharmaceuticals, a subsidiary of Canada-headquartered (...)

Reimbursement decisions in France and the UK led to revenue growth for one drug of 28.1 per cent in the first quarter of 2019 compared with a year earlier. Photograph: iStock

Irish pharmaceutical company Amryt said its revenues rose 13.3 per cent in 2018 to €14.5 million and the strong momentum continued into the first quar(...)

Dr Elaine Sullivan, Carrick Therapeutics, winner of the Emerging award at the EY Entrepreneur of the Year Awards, which took place in Citywest. Photograph: Dave Meehan for the Irish Times

Dr Elaine Sullivan, co-founder and chief executive of early-stage life-sciences company Carrick Therapeutics, has won top prize in the emerging catego(...)

Dublin-based Amryt said it’s making “strong progress” with its lead development asset, a drug for the treatment of Epidemolysis Bullosa (EB). Photograph: iStock

Sales of Amryt Pharma’s lead commercial drug increased 14.6 per cent in the first half of 2018 as the group significantly expanded the locations in wh(...)

Amryt said the US Food and Drug Administration had given it  approval which will enable the opening of US clinical trials on their drug AP101.

Irish pharmaceutical company Amryt said on Monday that it had received IND (investigational new drug) approval from the US authorities that will allow(...)

Amryt Pharma chief executive Joe Wiley.

Irish pharmaceutical company Amryt Pharma has won a designation for one of its key drugs which could make it eligible for a voucher ultimately worth u(...)

Amryt Pharma chief executive Joe Wiley said the move was another step on the road as the company looked to make the drug available in more territories.

Irish biopharmaceutical group Amryt Pharma’s flagship product Lojuxta has been approved for funding as an NHS England treatment for adults. Lojuxta i(...)

Amryt Pharma founder Dr Joe Wiley: “A good entrepreneur knows how to delegate.”

In 2015, Dr Joe Wiley founded Amryt Pharma to focus on acquiring, developing and delivering innovative treatments that help improve the lives of patie(...)

  • 1
  • 2
  • Next
  • Last »